Form 8-K PIONEER ENERGY SERVICES For: Jul 31
http://archive.fast-edgar.com/20140731/AR22V222R222L2Z22229223NFASCT2225262
Filed on: July 31, 2014
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTACâ„¢ molecule
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share